Ginseng extract studied for breast cancer effects

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with cytologically confirmed breast cancer with biopsy showing invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging * Surgical patients undergoing lumpectomy, subtotal or total mastectomy * 18 years of age or greater * female * available tissue blocks from diagnostic biopsy * negative pregnancy test, medical history of surgical sterilization, or 1 year post menopausal * must be willing to forego surgery for minimum of 5 days * ability and willingness to sign written consent * if hypertensive, on stable dose of medication at least 30 days * if diabetic, well controlled (HbA1C \< 8.5 within past 60 days or documented FPG \< 140 mg/dl for 3 consecutive days * ECOG status \< 2 or Karnofsky of 60% or greater Exclusion Criteria: * previous or current malignancy, excluding non-melanomic skin cancer * evidence of distant metastatic disease * history of chemotherapy, biologic or radiotherapy with 6 months of biopsy * usage of herbal supplements or alternative medications not approved by the FDA within 1 week of starting study drug. LEAG or related ginseng products, and combination products containing ginseng, should be discontinued within 6 weeks of starting study drug * history of allergic reactions attributed to compounds of similar chemical or biologic composition to LEAG * history of chronic inflammatory process, including, but not limited to, rheumatoid arthritis and lupus. This includes patients on concurrent systemic steroids or anti-inflammatory medications * active bleeding or a pathological condition that carries a high risk of bleeding * any swallowing dysfunction * uncontrolled intercurrent illness * poorly controlled diabetes (control indicated with HbA1c \< 8.5 within past 60 days or documented fasting blood glucose \< 140 mg/dl for three consecutive days) * known diabetics who have experienced episodes of symptomatic hypoglycemia in the last 6 months are also considered poorly controlled and will be excluded from study participation. * uncontrolled hypertension (SBP \> 140 mmHg or DBP \> 90 mmHG) * pregnant or breast feeding women Women must be willing to use birth control throughout study duration. * current investigational medications or treatment with an investigational agent within 6 weeks prior to biopsy * current coumadin therapy or who have been treated with coumadin within the 2 weeks prior to biopsy * current monoamine oxidase inhibitors treatment